Tissue factor: A conventional or alternative target in cancer therapy

Clinical Chemistry

Volumn 62, Issue 4, 2016, Pages 563-570

  Eisenreich, Andreas ^a   Bolbrinker, Juliane ^a   Leppert, Ulrike ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ISOPROTEIN; THROMBOPLASTIN; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ANGIOGENESIS; BIOLOGY; CANCER CELL; CANCER THERAPY; CELL MIGRATION; CELL PROLIFERATION; HUMAN; METASTASIS; NEOPLASM; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; THROMBOSIS; TUMOR GROWTH; TUMOR INVASION; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; GENETICS; METABOLISM; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY; PROTEIN PROCESSING;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN ISOFORMS; PROTEIN PROCESSING, POST-TRANSLATIONAL; THROMBOPLASTIN;

EID: 84962467421     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2015.241521     Document Type: Review

References (45)

1. Bauca JM, Martinez-Morillo E, Diamandis EP. Peptidomics ofurine and other biofluids for cancer diagnostics. Clin Chem 2014;60:1052-61.
2. Eisenreich A, Zakrzewicz A, Huber K, Thierbach H, Pepke W, Goldin-Lang P, et al. Regulation of pro-angiogenic tissue factor expression in hypoxia-induced human lung cancer cells. Oncol Rep 2013;30:462-70.
3. Goldin-Lang P, Tran QV, Fichtner I, Eisenreich A, Antoniak S, Schulze K, et al. Tissue factor expression pattern in human non-small cell lung cancer tissues indicate increased blood thrombogenicity and tumor metastasis. Oncol Rep 2008;20:123-8.
4. Regina S, Valentin JB, Lachot S, Lemarie E, Rollin J, Gruel Y. Increased tissue factor expression is associated with reduced survival in non-small cell lung cancer and with mutations of TP53 and PTEN. Clin Chem 2009;55: 1834-42.
5. Eisenreich A, Bogdanov VY, Zakrzewicz A, Pries A, Antoniak S, Poller W, et al. Cdc2-like kinases and DNA to-poisomerase I regulate alternative splicing of tissue factor in human endothelial cells. Circ Res 2009;104:589-99.
6. Versteeg HH. Tissue factor as anevolutionary conserved cytokine receptor: implications for inflammation and signal transduction. Semin Hematol 2004;41:168-72.
7. Bogdanov VY, Balasubramanian V, Hathcock J, Vele O, Lieb M, Nemerson Y. Alternatively spliced human tissue factor: a circulating, soluble, thrombogenic protein. Nat Med 2003;9:458-62.
8. Yu JL, Rak JW. Shedding of tissue factor (TF)-containing microparticles rather than alternatively spliced TF is the main source of TF activity released from human cancer cells. J Thromb Haemost 2004;2:2065-7.
9. Boltzen U, Eisenreich A, Antoniak S, Weithaeuser A, Fechner H, Poller W, et al. Alternatively spliced tissue factor and full-length tissue factor protect cardiomyocytes against TNF-alpha-induced apoptosis. J Mol Cell Cardiol 2012;52:1056-65.
10. Eisenreich A, Boltzen U, Malz R, Schultheiss HP, Rauch U. Overexpression of alternatively spliced tissue factor induces the pro-angiogenic properties of murine cardiomyocytic HL-1 cells. Circ J 2011;75:1235-42.
11. Chand HS, Ness SA, Kisiel W. Identification of a novel human tissue factorsplice variant that i supregulated in tumor cells. Int J Cancer 2006;118:1713-20.
12. Hobbs JE, Zakarija A, Cundiff DL, Doll JA, Hymen E, Cornwell M, et al. Alternatively spliced human tissue factor promotes tumor growth and angiogenesis in a pancreatic cancer tumor model. Thromb Res 2007; 120(Suppl 2):S13-21.
13. Versteeg HH, Schaffner F, Kerver M, Ellies LG, Andrade-Gordon P, Mueller BM, Ruf W. Protease-activated receptor (PAR) 2, but not PAR1, signaling promotes the development of mammary adenocarcinoma in polyoma middle T mice. Cancer Res 2008;68:7219-27.
14. Eisenreich A, Boltzen U, Poller W, Schultheiss HP, Rauch U. Effects of the Cdc2-like kinase-family and DNA topoisomerase I on the alternative splicing of eNOS in TNF-alpha-stimulated human endothelial cells. Biol Chem 2008;389:1333-8.
15. Eisenreich A, Rauch U. Regulation of the tissue factor isoform expression and thrombogenicity of HMEC-1 by miR-126 and miR-19a. Cell Biol 2013;2:1.
16. Zhang X, Yu H, Lou JR, Zheng J, Zhu H, Popescu NI, et al. MicroRNA-19 (miR-19) regulates tissue factor expression in breast cancer cells. J Biol Chem 2011;286: 1429-35.
17. Yu JL, May L, Lhotak V, Shahrzad S, Shirasawa S, Weitz JI, et al. Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis. Blood 2005;105: 1734-41.
18. Sun L, Liu Y, Lin S, Shang J, Liu J, Li J, et al. Early growth response gene-1 and hypoxia-inducible factor-1alpha affect tumor metastasis via regulation of tissue factor. Acta Oncol 2013;52:842-51.
19. Eisenreich A. Regulation of vascular function on post-transcriptional level. Thrombosis 2013;2013:948765.
20. Chandradas S, Deikus G, Tardos JG, Bogdanov VY. Antagonistic roles of four SR proteins in the biosynthesis of alternatively spliced tissue factortranscripts in monocytic cells. J Leukoc Biol 2010;87:147-52.
21. Kocatürk B, van den Berg YW, Tieken C, Mieog JS, de Kruijf EM, Engels CC, et al. Alternatively spliced tissue factor promotes breast cancer growth in a β1 integrin-dependent manner. Proc Natl Acad SciUSA 2013;110: 11517-22.
22. Ruf W, Disse J, Carneiro-Lobo TC, Yokota N, Schaffner F. Tissue factor and cell signalling in cancer progression and thrombosis. J Thromb Haemost 2011;9(Suppl 1): 306-15.
23. Hu L, Xia L, Zhou H, Wu B, Mu Y, Wu Y, Yan J. TF/FVIIa/PAR2 promotes cell proliferation and migration via PKCα and ERK-dependentc-Jun/AP-1 pathway in colon cancer cell line SW620. Tumour Biol 2013;34:2573-81.
24. van den Berg YW, van den Hengel LG, Myers HR, Ayachi O, Jordanova E, Ruf W, et al. Alternatively spliced tissue factor induces angiogenesis through integrin ligation. Proc Natl Acad Sci U S A 2009;106:19497-502.
25. Unruh D, Turner K, Srinivasan R, Kocaturk B, Qi X, Chu Z, et al. Alternatively spliced tissue factor contributes to tumor spread and activation of coagulation in pancreatic ductal adenocarcinoma. Int J Cancer 2014;134:9-20.
26. Davila M, Robles-Carrillo L, Unruh D, Huo Q, Gardiner C, Sargent IL, et al. Microparticle association and heterogeneity of tumor-derived tissue factor in plasma: is it important for coagulation activation? J Thromb Haemost 2014;12:186-96.
27. Zwicker JI, Liebman HA, Neuberg D, Lacroix R, Bauer KA, Furie BC, Furie B. Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy. Clin Cancer Res 2009;15:6830-40.
28. Davila M, Amirkhosravi A, Coll E, Desai H, Robles L, Colon J, et al. Tissue factor-bearing microparticles derived from tumor cells: impact on coagulation activation. J Thromb Haemost 2008;6:1517-24.
29. Geddings JE, Mackman N. New players in haemostasis and thrombosis. Thromb Haemost 2014;111:570-4.
30. Versteeg HH, Schaffner F, Kerver M, Petersen HH, Ahamed J, Felding-Habermann B, et al. Inhibition of tissue factor signaling suppresses tumor growth. Blood 2008;111:190-9.
31. Gauck S, Schultheiss HP, Rauch U, Eisenreich A. Modulation of the isoform expression of Cyr61 and Integrin-αv in human microvascular endothelial cells. Cardiovasc Syst 2013;1:8.
32. Dorfleutner A, Hintermann E, Tarui T, Takada Y, Ruf W. Cross-talk of integrin alpha3beta1 and tissue factor in cell migration. Mol Biol Cell 2004;15:4416-25.
33. Palumbo JS, Degen JL. Hemostatic factors in tumor biology. J Pediatr Hematol Oncol 2000;22:281-7.
34. Ruf W, Mueller BM. Tissue factor in cancer angiogenesis and metastasis. Curr Opin Hematol 1996;3:379-84.
35. Schaffner F, Ruf W. Tissue factor and protease-activated receptor signaling in cancer. Semin Thromb Hemost 2008;34:147-53.
36. Mueller BM, Reisfeld RA, Edgington TS, Ruf W. Expression of tissue factor by melanoma cells promotes efficient hematogenous metastasis. Proc Natl Acad Sci U S A 1992;89:11832-6.
37. Pengo V, Noventa F, Denas G, Pengo MF, Gallo U, Grion AM, et al. Long-term use of vitamin K antagonists and incidence of cancer: a population-based study. Blood 2011;117:1707-9.
38. Nakchbandi W, Muller H, Singer MV, Lohr M, Nakchbandi IA. Effects of low-dose warfarin and regional chemotherapy onsurvival inpatients with pancreatic carcinoma. Scand J Gastroenterol 2006;41:1095-104.
39. Hembrough TA, Swartz GM, Papathanassiu A, Vlasuk GP, Rote WE, Green SJ, Pribluda VS. Tissue factor/factor VIIa inhibitors block angiogenesis and tumor growth through a nonhemostatic mechanism. Cancer Res 2003;63:2997-3000.
40. Hu Z, Sun Y, Garen A. Targeting tumor vasculature endothelial cells and tumor cells for immunotherapy of human melanoma in a mouse xenograft model. Proc Natl Acad Sci U S A 1999;96:8161-6.
41. Breij EC, de Goeij BE, Verploegen S, Schuurhuis DH, Amirkhosravi A, Francis J, et al. An antibody-drug conjugate that targets tissue factor exhibits potent therapeutic activity against a broad range of solid tumors. Cancer Res 2014;74:1214-26.
42. Badimon JJ, Lettino M, Toschi V, Fuster V, Berrozpe M, Chesebro JH, Badimon L. Local inhibition of tissue factor reduces the thrombogenicity of disrupted human atherosclerotic plaques: effects of tissue factor pathway inhibitoronplaque thrombogenicity under flow conditions. Circulation 1999;99:1780-7.
43. Morrow DA, Murphy SA, McCabe CH, Mackman N, Wong HC, Antman EM. Potent inhibition of thrombin with a monoclonal antibody against tissue factor (Sunol-cH36): results of the PROXIMATE-TIMI 27 trial. Eur Heart J 2005;26:682-8.
44. Zoldhelyi P, Chen ZQ, Shelat HS, McNatt JM, Willerson JT. Local gene transfer of tissue factor pathway inhibitor regulates intimal hyperplasia in atherosclerotic arteries. Proc Natl Acad Sci U S A 2001;98:4078-83.
45. Abraham E, Reinhart K, Svoboda P, Seibert A, Olthoff D, Dal NA, et al. Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter, randomized, placebo-controlled, single-blind, dose escalation study. Crit Care Med 2001;29:2081-9.